Bristol Sets Positive, But Hesitant Tone About Nivolumab Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
The New York pharma talked about its anti-PD-1 drug for most of its year-end conference call, but managed to say very little about the success of the drug so far in clinical trials, disappointing analysts and investors.